Integra LifeSciences Holdings Corporation IART
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.66B | 1.65B | 1.64B | 1.64B | 1.64B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.66B | 1.65B | 1.64B | 1.64B | 1.64B |
| Cost of Revenue | 721.35M | 710.60M | 711.92M | 715.93M | 698.35M |
| Gross Profit | 935.44M | 937.07M | 932.59M | 919.31M | 944.62M |
| SG&A Expenses | 829.04M | 834.36M | 838.20M | 832.59M | 670.88M |
| Depreciation & Amortization | 15.07M | 15.04M | 15.03M | 14.95M | 14.90M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.86B | 1.85B | 1.86B | 1.86B | 1.47B |
| Operating Income | 232.14M | 229.98M | 222.36M | 213.05M | 172.56M |
| Income Before Tax | 22.31M | -179.00K | -535.88M | -563.50M | -545.27M |
| Income Tax Expenses | 9.30M | 7.06M | -40.08M | -47.03M | -49.94M |
| Earnings from Continuing Operations | 13.01 | -7.24 | -495.80 | -516.47 | -495.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.01M | -7.24M | -495.80M | -516.47M | -495.34M |
| EBIT | 232.14M | 229.98M | 222.36M | 213.05M | 172.56M |
| EBITDA | 424.62M | 421.92M | 413.86M | 403.31M | 330.65M |
| EPS Basic | 0.17 | -0.09 | -6.46 | -6.74 | -6.46 |
| Normalized Basic EPS | 0.97 | 0.90 | 0.81 | 0.73 | 0.90 |
| EPS Diluted | 0.17 | -0.10 | -6.47 | -6.74 | -6.46 |
| Normalized Diluted EPS | 0.96 | 0.90 | 0.81 | 0.73 | 0.90 |
| Average Basic Shares Outstanding | 308.41M | 307.77M | 307.18M | 306.69M | 306.33M |
| Average Diluted Shares Outstanding | 310.47M | 308.65M | 307.18M | 306.69M | 306.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |